ArticleOpen forum infectious diseases2026

Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years.

Andrea Calcagno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.